FDA Approvals Fuel ATTR-CM Therapeutics Expansion in the U.S.
The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market is experiencing transformative growth, led by next-generation therapeutics, increasing diagnosis rates, and strong regulatory momentum. Once considered underdiagnosed and undertreated, ATTR-CM is now at the center of groundbreaking drug innovations that are expanding access and improving outcomes. To Get Free Sample Report: https://www.datamintelligence.com/download-sample/transthyretin-amyloid-cardiomyopathy-market Market Size & Growth Projections The ATTR-CM treatment market was estimated at around USD 10.36 billion in 2024 and is expected to grow to more than USD 35 billion by 2029. Forecasts suggest an annual growth rate exceeding 28%, with some estimates reaching over USD 20 billion by 2033. Increasing patient awareness, expanding screening efforts, and new FDA approvals are accelerating this growth across both hereditary and wild-type ATTR-CM subtypes. Core Market Drivers 1. Rising Global Aging Population ATTR-...